Related Experiment Videos
Beta-blockers to reduce mortality in patients with systolic dysfunction: a meta-analysis
1Department of Pharmacy Practice, Medical University of South Carolina, Charleston, SC 29425, USA. leesj@musc.edu
The Journal of Family Practice
|June 13, 2001
Summary
Beta-blocker therapy, including bisoprolol, carvedilol, and metoprolol, significantly reduces mortality risk in patients with systolic heart failure. This meta-analysis confirms beta-blockers are crucial for managing heart failure patients.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Systolic dysfunction is a major cause of heart failure.
- Therapeutic options to reduce mortality in these patients are critical.
Purpose of the Study:
- To assess the efficacy of adrenergic beta-antagonists (beta-blockers) in reducing mortality in patients with systolic dysfunction.
- To analyze data from published clinical trials through meta-analysis.
Main Methods:
- Systematic review and meta-analysis of randomized, double-blinded, controlled clinical trials.
- Inclusion of trials with patients suffering from systolic heart failure.
- Assessment of mortality as a primary or secondary endpoint.
Main Results:
- Beta-blocker therapy (bisoprolol, carvedilol, metoprolol) showed statistically significant improvement in mortality.
- Pooled analysis demonstrated a significant reduction in total mortality (OR 0.66, 95% CI 0.58-0.75) and sudden death (OR 0.61, 95% CI 0.5-0.75).
Conclusions:
- Beta-blocker therapy with bisoprolol, carvedilol, or metoprolol is recommended for all patients with New York Heart Association class II and III heart failure.
- Ongoing trials will further elucidate optimal patient selection and preferred beta-blocker agents.